PL1874819T3 - Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów - Google Patents

Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów

Info

Publication number: PL1874819T3
Authority: PL; Poland
Prior art keywords: stimulating factor; colony stimulating; macrophage colony; granulocyte macrophage; human granulocyte
Prior art date: 2005-04-18

Application number

PL06724392T

Other languages

English (en)

Inventor

Tobias Raum

Hepp, (Née Henckel) Julia

Eva Vieser

Silke Petsch

Steven Zeman

Andreas Wolf

Sandra Bruckmaier

Original Assignee

Amgen Res Munich Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-18

Filing date

2006-04-18

Publication date

2015-10-30

2006-04-18 Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh

2015-10-30 Publication of PL1874819T3 publication Critical patent/PL1874819T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)

PL06724392T 2005-04-18 2006-04-18 Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów PL1874819T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05008410		2005-04-18
PCT/EP2006/003528 WO2006111353A2 (en)	2005-04-18	2006-04-18	Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP06724392.3A EP1874819B1 (en)	2005-04-18	2006-04-18	Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Publications (1)

Publication Number	Publication Date
PL1874819T3 true PL1874819T3 (pl)	2015-10-30

Family

ID=37115507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06724392T PL1874819T3 (pl)	2005-04-18	2006-04-18	Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów

Country Status (28)

Country	Link
US (3)	US8017748B2 (pl)
EP (2)	EP1874819B1 (pl)
JP (1)	JP5085533B2 (pl)
KR (2)	KR20150091193A (pl)
CN (2)	CN103342751B (pl)
AU (1)	AU2006237159B2 (pl)
BR (1)	BRPI0608281B8 (pl)
CA (1)	CA2605402C (pl)
CY (1)	CY1116632T1 (pl)
DK (1)	DK1874819T3 (pl)
EA (2)	EA017420B9 (pl)
ES (1)	ES2545769T3 (pl)
HR (1)	HRP20150773T1 (pl)
HU (1)	HUE025134T2 (pl)
IL (2)	IL186486A0 (pl)
ME (1)	ME02191B (pl)
MX (1)	MX2007012569A (pl)
NO (1)	NO344249B1 (pl)
NZ (1)	NZ562093A (pl)
PL (1)	PL1874819T3 (pl)
PT (1)	PT1874819E (pl)
RS (1)	RS54127B1 (pl)
RU (2)	RU2458071C2 (pl)
SG (1)	SG161292A1 (pl)
SI (1)	SI1874819T1 (pl)
UA (1)	UA94403C2 (pl)
WO (1)	WO2006111353A2 (pl)
ZA (1)	ZA200708201B (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20150091193A (ko)	2005-04-18	2015-08-07	암젠 리서치 (뮌헨) 게엠베하	인간 과립구 마크로파지 콜로니 자극 인자의 중화 항체
JP4736037B2 (ja)	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
RS55526B1 (sr) *	2006-02-08	2017-05-31	Morphotek Inc	Antigenski gm-csf peptidi i antitela gm-csf
US20080171038A1 (en) *	2006-11-08	2008-07-17	Kalobios Pharmaceuticals, Inc.	Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en)	2006-11-21	2013-03-19	Kalobios Pharmaceuticals, Inc.	Methods of treating dementia using a GM-CSF antagonist
EP2121755A1 (en) *	2007-02-08	2009-11-25	Merck & Co., Inc.	Antibodies specific for dkk-1
EP2160407A4 (en) *	2007-05-23	2011-07-27	Crc For Asthma And Airways Ltd	NEUTRALIZING ANTIBODIES
TW200918553A (en)	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
BRPI0820530A2 (pt) *	2007-11-13	2015-06-16	Boehringer Ingelheim Int	Anticorpos monoclonais que se ligam ao hgm-csf e composições medicinais compreendendo os mesmos
PT2708559T (pt) *	2008-04-11	2018-05-16	Chugai Pharmaceutical Co Ltd	Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
EA201001691A1 (ru)	2008-04-28	2011-10-31	Калобайос Фармасьютикалз, Инк.	Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
EA024654B1 (ru) *	2008-04-29	2016-10-31	Эмджен Рисерч (Мьюник) Гмбх	Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
RU2366422C1 (ru) *	2008-05-19	2009-09-10	Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской Академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН)	Способ коррекции депрессии гранулоцитопоэза при цитостатическом воздействии
RU2712273C2 (ru) *	2008-12-22	2020-01-28	Де Юниверсити Оф Мельбурн	Лечение остеоартрита
ES2978209T3 (es)	2008-12-22	2024-09-09	Univ Melbourne	Tratamiento del dolor
JP2012530047A (ja) *	2009-05-05	2012-11-29	モルフォシス・アー・ゲー	多発性硬化症のための治療
EP3604330A1 (en)	2011-02-25	2020-02-05	Chugai Seiyaku Kabushiki Kaisha	Fcgammariib-specific fc antibody
US20140234298A1 (en)	2011-07-06	2014-08-21	Morphosys Ag	Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
WO2013090989A1 (en)	2011-12-22	2013-06-27	Csl Limited	Method of treating inflammatory bowel disease
WO2014004549A2 (en)	2012-06-27	2014-01-03	Amgen Inc.	Anti-mesothelin binding proteins
EP2914289B1 (en)	2012-10-31	2019-05-22	Takeda GmbH	Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) *	2012-10-31	2015-05-27	Amgen Res Munich Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014138862A1 (en) *	2013-03-14	2014-09-18	John Schrader	Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
US10745475B2 (en) *	2013-08-30	2020-08-18	Takeda Gmbh	Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
WO2015028666A1 (en) *	2013-08-30	2015-03-05	Takeda Gmbh	Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis
US9765142B2 (en)	2013-10-11	2017-09-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	TEM8 antibodies and their use in treatment and detection of tumors
WO2015103549A1 (en)	2014-01-03	2015-07-09	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
BR112016025126B1 (pt) *	2014-05-07	2024-02-15	Takeda Pharmaceutical Company Limited	Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
WO2016077789A1 (en)	2014-11-14	2016-05-19	The Usa, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to ebola virus glycoprotein and their use
WO2016079276A1 (en) *	2014-11-21	2016-05-26	Takeda Gmbh	Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
WO2016079277A1 (en) *	2014-11-21	2016-05-26	Takeda Gmbh	Use of an anti-gm-csf antagonist in the treatment of an infectious disease
WO2016138160A1 (en)	2015-02-24	2016-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
GB201503139D0 (en) *	2015-02-25	2015-04-08	Univ Leicester	Diagnostic and therapeutic target
ES2789348T3 (es)	2015-03-20	2020-10-26	Us Health	Anticuerpos neutralizantes para GP120 y sus usos
EP3359570A1 (en)	2015-10-07	2018-08-15	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
GB201519331D0 (en) *	2015-11-02	2015-12-16	Glaxosmithkline Ip Dev Ltd	Treatment paradigm
CN115010805B (zh)	2015-11-03	2025-01-28	美国政府(由卫生和人类服务部的部长所代表)	Hiv-1 gp41中和抗体及其用途
WO2017192589A1 (en)	2016-05-02	2017-11-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to influenza ha and their use and identification
CN106872428A (zh) *	2017-02-07	2017-06-20	远见生物科技（上海）有限公司	一种用于检测中性粒细胞呼吸爆发功能的试剂盒
EP3580235B1 (en)	2017-02-10	2024-05-01	The United States of America, as represented by the Secretary, Department of Health and Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US10899831B2 (en)	2017-10-02	2021-01-26	Humanigen, Inc.	Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en)	2017-10-02	2021-02-23	Humanicen, Inc.	Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en)	2017-10-02	2021-09-28	Humanigen, Inc.	Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10870703B2 (en)	2017-10-02	2020-12-22	Humanigen, Inc.	Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
WO2019082869A1 (ja)	2017-10-24	2019-05-02	アドバンスト・ソフトマテリアルズ株式会社	低包接率ポリロタキサンの製造方法
US11976109B2 (en)	2018-01-02	2024-05-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to ebola virus glycoprotein and their use
CA3091437A1 (en)	2018-02-21	2019-08-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
CN112805301B (zh) *	2018-10-15	2023-07-21	安立玺荣生医(香港)有限公司	粒细胞-巨噬细胞集落刺激因子的抗体及其用途
US11078264B2 (en)	2018-10-17	2021-08-03	University Of Connecticut	Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
EP3883609A2 (en)	2018-12-20	2021-09-29	The United States of America, as represented by the Secretary, Department of Health and Human Services	Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
US12269872B2 (en)	2019-05-03	2025-04-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en)	2019-05-21	2023-03-16	University Of Georgia Research Foundation, Inc.	Antibodies that bind human metapneumovirus fusion protein and their use
EP3994173A1 (en)	2019-07-02	2022-05-11	The United States of America, as represented by the Secretary, Department of Health and Human Services	Monoclonal antibodies that bind egfrviii and their use
WO2021204649A1 (en)	2020-04-06	2021-10-14	Glaxosmithkline Intellectual Property Development Limited	Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022132904A1 (en)	2020-12-17	2022-06-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies targeting sars-cov-2
US20240117011A1 (en)	2021-02-09	2024-04-11	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Antibodies targeting the spike protein of coronaviruses
EP4291306A1 (en)	2021-02-09	2023-12-20	University of Georgia Research Foundation, Inc.	Human monoclonal antibodies against pneumococcal antigens
EP4402165A1 (en)	2021-09-17	2024-07-24	The United States of America, as represented by the Secretary, Department of Health and Human Services	Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
US20250145690A1 (en)	2022-02-10	2025-05-08	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that broadly target coronaviruses
EP4499228A1 (en)	2022-03-28	2025-02-05	The United States of America, as represented by the Secretary, Department of Health and Human Services	Neutralizing antibodies to hiv-1 env and their use
WO2024030829A1 (en)	2022-08-01	2024-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en)	2022-09-07	2024-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en)	2022-09-22	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
EP4638491A1 (en)	2022-12-19	2025-10-29	The United States of America, as represented by The Secretary, Department of Health and Human Services	Monoclonal antibodies for treating sars-cov-2 infection
WO2024138151A1 (en)	2022-12-22	2024-06-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
WO2024243355A1 (en)	2023-05-24	2024-11-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
WO2025014896A1 (en)	2023-07-07	2025-01-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Humanized 40h3 antibody
WO2025024233A1 (en)	2023-07-21	2025-01-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bispecific antibodies that broadly target coronaviruses
WO2025106427A1 (en)	2023-11-14	2025-05-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025117384A1 (en)	2023-12-01	2025-06-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2025137284A2 (en)	2023-12-21	2025-06-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8624899D0 (en) *	1986-10-17	1986-11-19	Sandoz Ltd	Monoclonal antibodies
US5070013A (en) *	1988-05-31	1991-12-03	Schering Corporation	Immunochemical assay for human granulocyte-macrophage colony stimulating factor
CA2060741A1 (en)	1991-02-11	1992-08-12	Robert S. Greenfield	Gm-csf inhibiting oligopeptides
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
DE69834032T2 (de)	1997-04-23	2006-12-07	Universität Zürich	Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
GB9722131D0 (en) *	1997-10-20	1997-12-17	Medical Res Council	Method
KR100508289B1 (ko)	1998-04-21	2005-08-17	마이크로메트 에이지	Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7157091B1 (en) *	1999-06-18	2007-01-02	Ludwig Institute For Cancer Research	MAGE-A1 peptides presented by HLA class II molecules
AU2001232267A1 (en)	2000-02-14	2001-08-20	Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases	Remedies for hepatitis c
US20050271663A1 (en) *	2001-06-28	2005-12-08	Domantis Limited	Compositions and methods for treating inflammatory disorders
ES2365606T3 (es) *	2002-02-13	2011-10-07	Ludwig Institute For Cancer Research Ltd.	Anticuerpos contra gm-csf quiméricos.
EP1593690B1 (en) *	2004-05-05	2009-07-01	Micromet AG	Preparation of ScFv antibody fragments
KR20150091193A (ko) *	2005-04-18	2015-08-07	암젠 리서치 (뮌헨) 게엠베하	인간 과립구 마크로파지 콜로니 자극 인자의 중화 항체
BRPI0610796B8 (pt)	2005-05-18	2021-05-25	Morphosys Ag	anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
RS55526B1 (sr)	2006-02-08	2017-05-31	Morphotek Inc	Antigenski gm-csf peptidi i antitela gm-csf

2006
- 2006-04-18 KR KR1020157020152A patent/KR20150091193A/ko not_active Abandoned
- 2006-04-18 PT PT67243923T patent/PT1874819E/pt unknown
- 2006-04-18 ME MEP-2015-111A patent/ME02191B/me unknown
- 2006-04-18 WO PCT/EP2006/003528 patent/WO2006111353A2/en not_active Ceased
- 2006-04-18 NZ NZ562093A patent/NZ562093A/en unknown
- 2006-04-18 MX MX2007012569A patent/MX2007012569A/es active IP Right Grant
- 2006-04-18 UA UAA200712125A patent/UA94403C2/ru unknown
- 2006-04-18 US US11/918,368 patent/US8017748B2/en active Active
- 2006-04-18 JP JP2008506992A patent/JP5085533B2/ja active Active
- 2006-04-18 SG SG201002699-5A patent/SG161292A1/en unknown
- 2006-04-18 RU RU2007138341/10A patent/RU2458071C2/ru active
- 2006-04-18 HR HRP20150773TT patent/HRP20150773T1/hr unknown
- 2006-04-18 EP EP06724392.3A patent/EP1874819B1/en active Active
- 2006-04-18 HU HUE06724392A patent/HUE025134T2/en unknown
- 2006-04-18 CA CA2605402A patent/CA2605402C/en active Active
- 2006-04-18 BR BRPI0608281A patent/BRPI0608281B8/pt active IP Right Grant
- 2006-04-18 EA EA200901500A patent/EA017420B9/ru unknown
- 2006-04-18 DK DK06724392.3T patent/DK1874819T3/en active
- 2006-04-18 KR KR1020077026929A patent/KR101704809B1/ko active Active
- 2006-04-18 ES ES06724392.3T patent/ES2545769T3/es active Active
- 2006-04-18 RS RS20150497A patent/RS54127B1/sr unknown
- 2006-04-18 AU AU2006237159A patent/AU2006237159B2/en active Active
- 2006-04-18 EA EA200702008A patent/EA013162B1/ru unknown
- 2006-04-18 CN CN201310231969.5A patent/CN103342751B/zh active Active
- 2006-04-18 SI SI200631960T patent/SI1874819T1/sl unknown
- 2006-04-18 EP EP12159883A patent/EP2468774A3/en not_active Ceased
- 2006-04-18 CN CN2006800188584A patent/CN101184777B/zh active Active
- 2006-04-18 PL PL06724392T patent/PL1874819T3/pl unknown
2007
- 2007-09-20 ZA ZA200708201A patent/ZA200708201B/en unknown
- 2007-10-08 IL IL186486A patent/IL186486A0/en not_active IP Right Cessation
- 2007-11-12 NO NO20075802A patent/NO344249B1/no unknown
2011
- 2011-08-04 US US13/198,558 patent/US9067993B2/en active Active
2012
- 2012-04-20 RU RU2012115683/10A patent/RU2012115683A/ru not_active Application Discontinuation
- 2012-06-14 IL IL220412A patent/IL220412A/en active IP Right Grant
2015
- 2015-05-21 US US14/718,923 patent/US10138297B2/en active Active
- 2015-08-20 CY CY20151100731T patent/CY1116632T1/el unknown

Also Published As

Publication number	Publication date
US8017748B2 (en)	2011-09-13
SG161292A1 (en)	2010-05-27
US9067993B2 (en)	2015-06-30
US20160130338A1 (en)	2016-05-12
BRPI0608281B1 (pt)	2020-01-28
EP1874819B1 (en)	2015-05-27
RS54127B1 (sr)	2015-12-31
BRPI0608281A2 (pt)	2009-12-15
HK1190161A1 (zh)	2014-06-27
WO2006111353A2 (en)	2006-10-26
UA94403C2 (ru)	2011-05-10
IL220412A0 (en)	2012-07-31
IL220412A (en)	2017-04-30
JP2008536505A (ja)	2008-09-11
JP5085533B2 (ja)	2012-11-28
AU2006237159B2 (en)	2011-03-24
DK1874819T3 (en)	2015-08-31
RU2007138341A (ru)	2009-05-27
US20120009195A1 (en)	2012-01-12
CN101184777B (zh)	2013-07-17
EP1874819A2 (en)	2008-01-09
EA013162B1 (ru)	2010-02-26
ZA200708201B (en)	2008-07-30
KR20150091193A (ko)	2015-08-07
HK1112003A1 (en)	2008-08-22
CY1116632T1 (el)	2017-03-15
US10138297B2 (en)	2018-11-27
WO2006111353A3 (en)	2007-04-19
NO344249B1 (no)	2019-10-21
CN103342751A (zh)	2013-10-09
ME02191B (me)	2016-02-20
HRP20150773T1 (hr)	2015-08-28
EA200702008A1 (ru)	2008-06-30
CN101184777A (zh)	2008-05-21
NZ562093A (en)	2011-01-28
EP2468774A3 (en)	2013-01-02
RU2458071C2 (ru)	2012-08-10
EP2468774A2 (en)	2012-06-27
KR20080005962A (ko)	2008-01-15
EA017420B9 (ru)	2013-03-29
SI1874819T1 (sl)	2015-09-30
US20090297532A1 (en)	2009-12-03
HUE025134T2 (en)	2016-01-28
ES2545769T3 (es)	2015-09-15
KR101704809B1 (ko)	2017-02-08
BRPI0608281B8 (pt)	2021-05-25
MX2007012569A (es)	2007-12-06
CA2605402A1 (en)	2006-10-26
AU2006237159A1 (en)	2006-10-26
PT1874819E (pt)	2015-09-17
NO20075802L (no)	2008-01-10
CN103342751B (zh)	2015-12-23
EA200901500A1 (ru)	2010-10-29
RU2012115683A (ru)	2013-10-27
EA017420B1 (ru)	2012-12-28
IL186486A0 (en)	2008-01-20
CA2605402C (en)	2017-05-23

Publication	Publication Date	Title
PL1874819T3 (pl)	2015-10-30	Przeciwciała neutralizujące ludzki czynnik stymulujący wzrost kolonii granulocytów i makrofagów
IL184506A0 (en)	2007-10-31	Glycopegylated granulocyte colony stimulating factor
LTC1971366I2 (lt)	2019-06-25	Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
IL211684A0 (en)	2011-06-30	Antibodies against human il 17 and uses thereof
ZA201103723B (en)	2012-09-26	Human antibodies against human tissue factor
LT3620171T (lt)	2022-06-10	Anti-gm-csf antikūnai ir jų panaudojimas
IL193605A0 (en)	2011-08-01	Antibodies against human il-22 and uses therefor
IL185747A0 (en)	2008-01-06	Use of supplemental assignments
IL184036A0 (en)	2007-10-31	Preparation of rosuvastatin
ZA201001903B (en)	2010-11-24	Use of human cells of myeloid leukaemia for expression of antibodies
IL193604A (en)	2013-07-31	Use of human anti-22 @ il antibodies for @ preparation
ZA200906516B (en)	2010-05-26	Novel human anti-R7V antibodies and uses thereof
IL185097A0 (en)	2007-12-03	Tissue specific expression of antibodies in chickens
EP1896081A4 (en)	2011-05-25	HUMAN FACTOR ISOFORMS OF STIMULATION OF GRANULAR COLONIES
IL187948A0 (en)	2008-03-20	Preparation of rosuvastatin
GB0509671D0 (en)	2005-06-15	Analysis of wood
GB0508356D0 (en)	2005-06-01	Materials and methods relating to the diagnosis of cancer
GB0715133D0 (en)	2007-09-12	Granulocyte colony stimulating factor
GB0724013D0 (en)	2008-01-23	Granulocyte colony stimulating factor
TWI317830B (en)	2009-12-01	Structure of back cover
ZA200706242B (en)	2008-12-31	Glycopegylated granulocyte colony stimulating factor
GB0605209D0 (en)	2006-04-26	Examination chair
GB0506945D0 (en)	2005-05-11	Human antibodies
GB0502201D0 (en)	2005-03-09	Human antibodies
SG10202006468XA (en)	2020-08-28	Human antibodies against human tissue factor